Abstract: A microsphere and methods for forming the same are disclosed. The microsphere includes modified cellulose and at least one first microsphere disposed within a multi-encapsulating microsphere, the at least one first microsphere comprising at least one first hydrogel precursor; and at least one second microsphere disposed within the multi-encapsulating microsphere, the at least one second microsphere comprising at least one second hydrogel precursor cross-linkable with the at least one first hydrogel precursor upon degradation of the at least one first microsphere and the at least one second microsphere.

Abstract: A microsphere and methods for forming the same are disclosed. The microsphere includes modified cellulose and at least one of precursors for is-situ polymerization or endothermic/exothermic reactions.

Abstract: The present invention relates to novel crystalline forms of naltrexone hydrochloride including hydrated and solvated forms and a novel amorphous form. The invention also describes methods of preparing the various crystalline forms. The present invention also relates to pharmaceutical compositions containing crystalline and amorphous forms of naltrexone hydrochloride, as well as methods of treating addictive behavior by administering the pharmaceutical compositions.

Abstract: The present invention relates to novel crystalline forms of naltrexone methobromide including hydrated and solvated forms. The invention also describes methods of preparing the various crystalline forms. The present invention also relates to pharmaceutical compositions containing crystalline forms of naltrexone methobromide, as well as methods of treating or preventing opioid induced side effects by administering the pharmaceutical compositions.

Abstract: The present invention provides polymorphs of 6-beta-naltrexol and process for their preparation. In particular, the present invention provides crystalline forms of the free base of 6-beta-naltrexol and processes for their preparation. The present invention also provides crystalline and amorphous forms of the hydrochloride salt of 6-beta-naltrexol and processes for their preparation.

Abstract: The present invention relates to novel crystalline forms of naltrexone methobromide including hydrated and solvated forms. The invention also describes methods of preparing the various crystalline forms. The present invention also relates to pharmaceutical compositions containing crystalline forms of naltrexone methobromide, as well as methods of treating or preventing opioid induced side effects by administering the pharmaceutical compositions.

Abstract: The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of solid materials that are used in industrial or consumer products.

Abstract: The present invention relates to novel crystalline forms of naltrexone hydrochloride including hydrated and solvated forms and a novel amorphous form. The invention also describes methods of preparing the various crystalline forms. The present invention also relates to pharmaceutical compositions containing crystalline and amorphous forms of naltrexone hydrochloride, as well as methods of treating addictive behavior by administering the pharmaceutical compositions.

Abstract: A highly pure crystalline form of benzphetamine hydrochloride and methods for the purification and crystallization of benzphetamine hydrochloride in high yield are disclosed.

Abstract: The present invention provides crystalline forms of fentanyl alkaloid and methods for preparing crystalline forms of fentanyl alkaloid.

Abstract: The present invention provides polymorphs of 6-beta-naltrexol and process for their preparation. In particular, the present invention provides crystalline forms of the free base of 6-beta-naltrexol and processes for their preparation. The present invention also provides crystalline and amorphous forms of the hydrochloride salt of 6-beta-naltrexol and processes for their preparation.

Abstract: The present invention provides crystalline forms of sufentanil citrate and methods for preparing crystalline forms of sufentanil citrate.

Abstract: The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of bioactive formulations including pharmaceutical compositions.

Abstract: An electronic throttle control system and method for detecting a throttle plate obstruction when the ignition key is on and the engine is either not running or running, and for clearing the throttle plate obstruction before a fault setting is set by the ECU.

Abstract: The present invention relates to a crystalline polymorphic form of remifentanil hydrochloride. The invention also describes methods of preparing a polymorphic form of remifentanil hydrochloride.

Abstract: An electronic throttle control system and method for detecting a throttle plate obstruction when the ignition key is on and the engine is either not running or running, and for clearing the throttle plate obstruction before a fault setting is set by the ECU.

Abstract: An electronic throttle control system and method which prevents obstructions from forming around a throttle plate during engine soak.

Abstract: An electronic throttle control system and method which prevents obstructions from forming around a throttle plate during engine soak.

Abstract: The present invention relates to novel crystalline polymorphic forms of levorphanol including hydrated, solvated, and non-hydrated (non-solvated) forms. The invention also describes methods of preparing the various polymorphic forms. The present invention also relates to pharmaceutical compositions containing crystalline polymorphs of levorphanol, as well as methods of relieving pain by administering the pharmaceutical compositions.

Abstract: A method for throttle progression control to minimize tip-in noise of an internal combustion engine by allowing the engine to receive only the required air for the commanded engine acceleration. The method comprises the steps of a) providing an electronically controlled throttle body and valve, b) providing an electronic control module, c) determining the engine air flow required to satisfy a desired engine acceleration, d) providing an input to the electronic control module corresponding to the engine air flow required, e) programming the electronic control module to limit the inflow of air during engine acceleration to match the engine air flow required for achieving said desired engine acceleration, and f) actuating the throttle body and valve to provide the limited air flow through the throttle body during the desired engine acceleration.